Table 1 Patient characteristics
Characteristic | Patients, n (%) |
|---|---|
Age at IO Therapy (years) | |
  ≤ 50 | 5 (8%) |
 51–60 | 14 (21%) |
 61–70 | 21 (31%) |
  > 70 | 27 (40%) |
Sex | |
 Female | 31 (46%) |
 Male | 36 (54%) |
Race | |
 African American | 20 (30%) |
 Caucasian | 47 (70%) |
Disease Stage | |
 Stage 2a | 2 (3%) |
 Stage 3 | 9 (13%) |
 Stage 4 | 56 (84%) |
Histology | |
 Adenocarcinoma | 36 (54%) |
 Squamous | 17 (25%) |
 Adenosquamous | 2 (3%) |
 NOS | 12 (18%) |
Biopsy Site | |
 Primary carcinoma | 30 (45%) |
 Distant metastases | 37 (55%) |
ECOG performance status | |
 0 | 23 (34%) |
 1 | 30 (45%) |
 2 | 14 (21%) |
Type of Therapy | |
 ICI Monotherapy | 57 (85%) |
 ICI + Chemotherapy | 10 (15%) |
ICI therapy received | |
 Nivolumab | 33 (49%) |
 Pembrolizumab | 32 (48%) |
 Nivolumab/ Pembrolizumab | 1 (1%) |
 Atezolizumab | 1 (1%) |
Line of Therapy | |
 1st line | 29 (43%) |
 2nd line + | 38 (57%) |
Response Status | |
 Response (CR, PR) | 42 (63%) |
 Non-Response (PD, SD) | 25 (37%) |
IO Score (≥0.09) | |
 Positive, n (%) | 36 (54%) |
 Negative, n (%) | 31 (46%) |
PD-L1 TPS (≥1%) | |
 Positive, n (%) | 45 (67%) |
 Negative, n (%) | 14 (21%) |
 Missing, n (%) | 8 (12%) |
TMB (≥10 mut/MB) | |
 Positive, n (%) | 21 (31%) |
 Negative, n (%) | 15 (22%) |
 Missing, n (%) | 31 (46%) |